Tempus AI reported stronger-than-expected Q2 results, citing a 31% year-over-year increase in its oncology testing business and raising full-year 2026 revenue guidance to between $1.6 billion and $1.61 billion. The company said FDA approvals for its xT CDx tumor-only platform and ongoing review of its xF liquid biopsy test are underpinning additional revenue uplift, while its planned acquisition of Personalis is expected to accelerate minimal residual disease testing adoption.